 CAMBRIDGE, Mass., March 18, 2021 GLOBE NEWSWIRE -- Solid Biosciences Inc., Nasdaq: SLDB a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy Duchenne, today announced that it has priced an underwritten public offering of 21,739,131 shares of its common stock at a public offering price of 5.75 per share, for total gross proceeds of 125.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Solid has granted the underwriters a 30-day option to purchase up to an additional 3,260,869 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Solid. The offering is expected to close on March 23, 2021, subject to customary closing conditions. 